Adamas believes in the power and the promise of medicines derived from a deep understanding of time-dependent biology. All biological processes, including the body’s responses to disease and drug interventions, are governed by complex timing patterns. When the timing of disease and drug responses are out of sync, patient outcomes can be compromised.
The company’s expertise lies in uncovering and mapping the relationship between disease and drug activity. From there, Adamas strives to create medicines with therapeutic profiles that match the pattern of disease to drive a more significant and durable clinical effect. As a result, the medicines are designed to provide patients with what they need, when they need it: the right level of drug at the right place and time to enhance efficacy, and then lower levels of drug when they don’t need it.
Adamas’ first product, GOCOVRI™ (amantadine) extended release capsuled (previously ADS-5102), was recently approved in the U.S. GOCOVRI is the first and only medicine approved for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is a high dose 274 mg amantadine (equivalent to 340 mg amantadine HCl) taken once-daily at bedtime, which delivers consistently high levels of amantadine in the morning and throughout the day when dyskinesia is most prevalent. GOCOVRI received orphan designation by the FDA in 2016.
If you have already created an account, please click on Login above to login.
Below is a list of our current job opportunities. For more information click on a job title that interests you. If you do not find a job that interests you, please select 'Submit Resume' above to submit your resume for future consideration.
SEARCH OPEN POSITIONS
We currently have no openings, please check back soon.